This Could Be The Way To Capitalize On The Trillion Dollar Healthcare Sector
There are only a few things that are certain in life— one of them being that without your health, you have nothing. Health is absolutely wealth... in more ways than one.
Global healthcare spending has been steadily climbing. We spent $7.6 trillion on our health in 2016 and $7.8 trillion in 2017. What seems like a small decimal point is a monumental increase when you’re talking TRILLIONS. That’s about 10 percent of GDP.
The global economy grew 3 percent each year between 2000 and 2017. Healthcare spending grew 3.9 percent each year. So yes, the health sector is actually expanding significantly faster than the global economy.
To top it all off— high income countries, like the United States, account for approximately 80 percent of global health spending.
I could go on, but at this point you may be asking, so how do I get in on this?
Odyssey Group International (OTCQB: ODYY) is a technology and asset acquisition company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions.
The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
The Medical technology industry is a prominent part of the healthcare sector— about $430 billion dollars kinda prominent, to be more exact. And with Odyssey’s current life-changing projects, they plan to be a key piece of the sector that has (what seems like) absolutely no limit.
The United States is home to the largest medical device market in the world— making up $156 billion, or about 40 percent of the global market, in 2017. This number is expected to grow to a whopping $208 billion by 2023.
Thus, California-headquartered Odyssey Group International (OTCQB: ODYY) has found themselves in a prime position to potentially dominate the market.
Its American roots are far from the only thing propelling Odyssey forward. They intend to commercialize each product primarily through one of three methods:
- A sale of the technology
- Licensing of the product to a distributor or manufacturer
- By manufacturing, marketing and directly selling the products themselves
With this model, Odyssey expects to provide many advantages to their shareholders and valued partners- some of which include:
- A more efficient and effective research and development process
- A quicker time to market with a distinguished go-to-market model after completion of development
- The value-added growth to the hub company, Odyssey Group International, through commercialization and subsidiary spin-off for maximum returns to the company and its shareholders.
Not to mention, Odyssey’s careful selection of technologies, partnerships, and acquisitions that appeal to the needs of BILLIONS across the globe.
THE CARDIOLOGY MARKET
Now let’s discuss the multi-billion dollar cardiology market. The market for cardiovascular devices (yes, just the devices) hit $42.4 billion globally in 2017. By 2022, it is expected to grow significantly— up to $59.1 billion significantly.
As more and more people each year get diagnosed with various forms of heart disease, these life- saving devices are an absolute necessity— and Odyssey Group International’s (OTCQB: ODYY) initial product technology, CardioMap®, is well poised to take the market by storm with its unique technology and portable design.
CardioMap is heart monitoring and screening device that provides early, non-invasive heart disease testing. Its highly portable design and web-based analysis is set to penetrate the multi- billion dollar cardiac device market, and also expand the market vertical by making remote and at- home screening a very real possibility.
Cardiovascular disease is one of the leading causes of the death in the world, and Odyssey hopes to change all of that with CardioMap.
When FDA approved, CardioMap will be the ONLY device in the world that has a predictive value — the only device capable of mass screening for early detection. All current methods either define patients as “healthy” or “sick,” while CardioMap can show grey areas where deterioration has begun— an incredible incentive for doctors to adopt the device.
Odyssey Chairman and Chief Executive Officer Michael Redmond, commented,
“CardioMap is a unique technology that can meet an unmet need in a large and growing market. We feel very confident that we can capitalize on the CardioMap opportunity to increase patient care and create significant shareholder value. In addition to CardioMap, Odyssey has acquired another medical device technology and has other acquisition targets it is pursuing.”
THERE IS CURRENTLY NO OTHER CONCUSSION TREATMENT DRUG
A Traumatic brain injury (TBI) is a major cause of death and disability in the United States. From 2006 to 2014, the number of TBI-related emergency department visits, hospitalizations, and deaths increased by 53%. In 2014, an average of 155 people in the United States died each day from injuries that include a TBI. Those who survive a TBI can face effects that last a few days, or the rest of their lives.
A concussion is a common form of traumatic brain injury— so common, in fact, that brain injuries cause more deaths than any other sports injury.
Odyssey Group International (OTCQB: ODYY) has recently partnered with Prevacus Inc., a company that has been developing a nasal spray to treat concussions.
Prevacus, Inc. is a biopharmaceutical
company which is developing drug
candidates that have the potential to
advance treatment in the fields of
traumatic brain injury and other
neurological disorders. The Company's
first two development candidates
(PRV-002 and PreVPro) represent
breakthrough strategy for treating
concussion working at the molecular level
to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.
Currently, there are no drugs available for concussion treatment. Prevacus’ founder, Jacob VanLandingham, is a Ph.D. who worked in the Department of Biomedical Sciences for the FSU College of Medicine. He has spent many years in the laboratory analyzing the positive effects neuro-steroids have on edema– swelling of the brain.
The Odyssey-Prevacus partnership could quite possibly facilitate the release of the FIRST EVER concussion treatment drug. Which would be an IMMENSE feat in an untouched market. The nasal spray is currently in the early stages of testing.
THIS COULD BE AS BIG AS THE BABY MONITOR
Choking events, or the obstruction of ones airway, are fairly common in both children and adults, and in mere minutes, they can lead to a fatal outcome.
There are approximately 5,000 choking deaths annually in the US, and of these deaths, 95% result from in-home incidents— when a lack of knowledge and preparation can be the difference between life and death.
Choking is the fourth leading cause of unintentional death, with the young and elderly being primarily affected. In fact, it is the LEADING cause of infantile death. Unfortunately, the life-saving Heimlich maneuver should never be used on children who are younger than one year. So what do you do if this horrifying event were to occur?
Odyssey Group International (OTCQB: ODYY) has acquired Second Chance, a company that has developed a personal anti-choking device.
The Second Chance is a patented, safe, and easy to use vacuum device for removing a lodged mass from the throat of a choking victim. The device includes a pump for creating a vacuum chamber which is connected seamlessly with a replaceable/disposable mouthpiece. In an emergency, the CRD may be easily inserted into the victim’s mouth which depresses the tongue providing a clear, trauma-free application.
Some of the many advantages of the Second Chance CRD include:
- It's easy to use
- Has a smart patented design
- Can be used on anyone (of any age)
- The product can be self-administrable
Anti-choking devices could soon be standard in households, with it being particularly important in the infant market. Like baby monitors, Odyssey sees no reason why the Second Chance CRD will not be absolutely vital to young families.
The Company’s senior management team and leadership have significant experience and capabilities to further refine the acquired technologies, build commercial systems and/or create strategic partnerships.
Odyssey Group International (OTCQB: ODYY) Board of Directors is made up of industry veterans that have successfully led publicly held medical companies with sustained growth and profitability.
Michael Redmond – CEO and Chairman of the Board of Directors: Commercial leadership experience in public medical device companies including Abbott Laboratories, Bioject Inc. and KMC Medical Systems Inc. Previous experience as CEO of publicly held Parallax Health Sciences Inc.
Jeff Conroy – Director: Jeff is currently CEO of Embody Inc. Jeff brings 30 years experience in forming strategic alliances and commercializing products in the Life Sciences and Medical Device markets. As founder of both Adjuvant Partners and Windward Investments, Jeff has provided advisory services for turn around, strategy and licensing to pharmaceutical, biotech and medical device companies since 1999. Jeff has also served as the Principle Licensing Officer for Especificos Stendhal S.A. de C.V. a Latin America specialty pharmaceutical company where he completed over $4B in licensing and partnership arrangements. Jeff is a Director and past Chairman of the Virginia Biotech Association.
LOOKING TOWARDS THE FUTURE
With trillions of dollars being spent on healthcare every single year, a number that is only expected to grow— and grow big, investing in medical technology could prove to be extremely beneficial. In relation to the sector, many things are certain:
- The population is aging— baby boomers in particular
- People are now living longer with chronic diseases
- Obesity and diabetes are epidemics
- Technology will continue to advance
- Disease has a global reach
- Medicine is becoming more personalized
It is rare to find such certainties when considering an investment, which is why Odyssey plans to use them to their advantage.
Odyssey Group International (OTCQB: ODYY) overall goal is to deliver financial results, which yield high rates of returns for both shareholders and partners. Their incredible technological advancements, most of which are found nowhere else, life-saving devices, and vastly experienced team should give you every reason to believe they will absolutely excel in the sector.
Disclaimer: Pursuant to an agreement between Quantum Capital and DearWallstreet.com, we were hired to publicly disseminate information about (( ODYY )) including on the Website and other media including Facebook and Twitter. We were paid up to $300k in cash from Quantum Capital. We own zero shares of (( ODYY )) which we purchased in the open market. We may buy or sell additional shares of (( ODYY )) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.